Prostate cancer and hypofractionation: really a new standard of care?

Affiliations

Editorial

Christian Carrie et al. Transl Androl Urol. 2016 Dec.

. 2016 Dec;5(6):966-967.

doi: 10.21037/tau.2016.08.19.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results.
Dearnaley D, Hall E. Dearnaley D, et al. Transl Androl Urol. 2017 Feb;6(1):134-136. doi: 10.21037/tau.2017.01.05. Transl Androl Urol. 2017. PMID: 28217463 Free PMC article. No abstract available.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Dearnaley D, et al. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339115 Free PMC article. Clinical Trial.

1. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60. 10.1016/S1470-2045(16)30102-4 - DOI - PMC - PubMed
1. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-8. 10.1016/j.ijrobp.2009.07.1691 - DOI - PubMed
1. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061-9. 10.1016/S1470-2045(16)30070-5 - DOI - PubMed